![]() Back to Annual Meeting
|
|
![]() Back to Annual Meeting
|
APHA Scientific Session and Event Listing |
Aimee R. Bolen, MPH1, Paul K. Henneberger, ScD2, Susan J. Derk, MA3, and Xiaoming Liang, MS2. (1) Health Research and Analysis, 5410 Edson Lane, Suite 320 G, Rockville, MD 20852, 301-468-7370, abolen@health-ra.com, (2) DRDS, NIOSH, MS 2800, 1095 Willowdale Rd., Morgantown, WV 26505, (3) DSR, NIOSH, MS 1808, 1095 Willowdale Rd., Morgantown, WV 26505
A subset of adults with asthma demonstrate irreversible airway obstruction (IAO) or other decrements in lung function. The aim of this study was to examine whether a history of workplace exacerbation of asthma (WEA) was associated with these outcomes in adults with asthma.
170 adults aged 20-47 (mean age=36) underwent lung function testing pre- and post- bronchodilator. Forced expiratory volume in one second (FEV1) and forced vital capacity (FVC) were measured. Obstruction was defined as a pre-bronchodilator FEV1 and FEV1/FVC less than the lower limits of normal (LLN). IAO was defined, among those obstructed, as a post-bronchodilator (post-BD) FEV1 less then the LLN. Associations between lung function outcomes and WEA and other variables were evaluated using regression modeling.
Fifteen (8.8%) of the 170 adults tested had IAO. Demographic characteristics, asthma severity, and WEA status were not associated with IAO. Based on regression modeling, a lower post-BD FEV1 was associated with moderately severe (versus mild) asthma among males (-0.371 liter, p=0.02) but not females (+0.106 liter, p=0.30), controlling for gender, age, height, and weight. Also, those with a history of WEA had a lower post-BD FEV1 (-0.179 liter, p=0.08).
Our study showed no association between IAO and traditional explanatory factors, but did show that IAO can occur in young adults with mild to moderate asthma. A decrement in FEV1 was associated with WEA, but was of borderline statistical significance (0.05<p<0.10) in this relatively small group of adults with asthma.
Learning Objectives:
Presenting author's disclosure statement:
Any relevant financial relationships? No
Any institutionally-contracted trials related to this submission?
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.
The 135th APHA Annual Meeting & Exposition (November 3-7, 2007) of APHA